French pharma giant Sanofi (SNY) recently announced that it has agreed to acquire Massachusetts-based biotech Vigil Neuroscience (VIGL) for a total equity value of around $470 million.The acquisition will boost Sanofi’s neurology pipeline by adding Vigil’s investigational oral small-molecule TREM2 agonist, VG-3927, which is being developed as a potential treatment for Alzheimer’s disease.A phase II study will evaluate VG-3927 in Alzheimer’s disease.TREM2 is a protein key for immune cell function, particular ...